Cargando…

Randomized controlled trials in de-implementation research: a systematic scoping review

BACKGROUND: Healthcare costs are rising, and a substantial proportion of medical care is of little value. De-implementation of low-value practices is important for improving overall health outcomes and reducing costs. We aimed to identify and synthesize randomized controlled trials (RCTs) on de-impl...

Descripción completa

Detalles Bibliográficos
Autores principales: Raudasoja, Aleksi J., Falkenbach, Petra, Vernooij, Robin W. M., Mustonen, Jussi M. J., Agarwal, Arnav, Aoki, Yoshitaka, Blanker, Marco H., Cartwright, Rufus, Garcia-Perdomo, Herney A., Kilpeläinen, Tuomas P., Lainiala, Olli, Lamberg, Tiina, Nevalainen, Olli P. O., Raittio, Eero, Richard, Patrick O., Violette, Philippe D., Komulainen, Jorma, Sipilä, Raija, Tikkinen, Kari A. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526943/
https://www.ncbi.nlm.nih.gov/pubmed/36183140
http://dx.doi.org/10.1186/s13012-022-01238-z
_version_ 1784800982058663936
author Raudasoja, Aleksi J.
Falkenbach, Petra
Vernooij, Robin W. M.
Mustonen, Jussi M. J.
Agarwal, Arnav
Aoki, Yoshitaka
Blanker, Marco H.
Cartwright, Rufus
Garcia-Perdomo, Herney A.
Kilpeläinen, Tuomas P.
Lainiala, Olli
Lamberg, Tiina
Nevalainen, Olli P. O.
Raittio, Eero
Richard, Patrick O.
Violette, Philippe D.
Komulainen, Jorma
Sipilä, Raija
Tikkinen, Kari A. O.
author_facet Raudasoja, Aleksi J.
Falkenbach, Petra
Vernooij, Robin W. M.
Mustonen, Jussi M. J.
Agarwal, Arnav
Aoki, Yoshitaka
Blanker, Marco H.
Cartwright, Rufus
Garcia-Perdomo, Herney A.
Kilpeläinen, Tuomas P.
Lainiala, Olli
Lamberg, Tiina
Nevalainen, Olli P. O.
Raittio, Eero
Richard, Patrick O.
Violette, Philippe D.
Komulainen, Jorma
Sipilä, Raija
Tikkinen, Kari A. O.
author_sort Raudasoja, Aleksi J.
collection PubMed
description BACKGROUND: Healthcare costs are rising, and a substantial proportion of medical care is of little value. De-implementation of low-value practices is important for improving overall health outcomes and reducing costs. We aimed to identify and synthesize randomized controlled trials (RCTs) on de-implementation interventions and to provide guidance to improve future research. METHODS: MEDLINE and Scopus up to May 24, 2021, for individual and cluster RCTs comparing de-implementation interventions to usual care, another intervention, or placebo. We applied independent duplicate assessment of eligibility, study characteristics, outcomes, intervention categories, implementation theories, and risk of bias. RESULTS: Of the 227 eligible trials, 145 (64%) were cluster randomized trials (median 24 clusters; median follow-up time 305 days), and 82 (36%) were individually randomized trials (median follow-up time 274 days). Of the trials, 118 (52%) were published after 2010, 149 (66%) were conducted in a primary care setting, 163 (72%) aimed to reduce the use of drug treatment, 194 (85%) measured the total volume of care, and 64 (28%) low-value care use as outcomes. Of the trials, 48 (21%) described a theoretical basis for the intervention, and 40 (18%) had the study tailored by context-specific factors. Of the de-implementation interventions, 193 (85%) were targeted at physicians, 115 (51%) tested educational sessions, and 152 (67%) multicomponent interventions. Missing data led to high risk of bias in 137 (60%) trials, followed by baseline imbalances in 99 (44%), and deficiencies in allocation concealment in 56 (25%). CONCLUSIONS: De-implementation trials were mainly conducted in primary care and typically aimed to reduce low-value drug treatments. Limitations of current de-implementation research may have led to unreliable effect estimates and decreased clinical applicability of studied de-implementation strategies. We identified potential research gaps, including de-implementation in secondary and tertiary care settings, and interventions targeted at other than physicians. Future trials could be improved by favoring simpler intervention designs, better control of potential confounders, larger number of clusters in cluster trials, considering context-specific factors when planning the intervention (tailoring), and using a theoretical basis in intervention design. REGISTRATION: OSF Open Science Framework hk4b2 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13012-022-01238-z.
format Online
Article
Text
id pubmed-9526943
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95269432022-10-03 Randomized controlled trials in de-implementation research: a systematic scoping review Raudasoja, Aleksi J. Falkenbach, Petra Vernooij, Robin W. M. Mustonen, Jussi M. J. Agarwal, Arnav Aoki, Yoshitaka Blanker, Marco H. Cartwright, Rufus Garcia-Perdomo, Herney A. Kilpeläinen, Tuomas P. Lainiala, Olli Lamberg, Tiina Nevalainen, Olli P. O. Raittio, Eero Richard, Patrick O. Violette, Philippe D. Komulainen, Jorma Sipilä, Raija Tikkinen, Kari A. O. Implement Sci Systematic Review BACKGROUND: Healthcare costs are rising, and a substantial proportion of medical care is of little value. De-implementation of low-value practices is important for improving overall health outcomes and reducing costs. We aimed to identify and synthesize randomized controlled trials (RCTs) on de-implementation interventions and to provide guidance to improve future research. METHODS: MEDLINE and Scopus up to May 24, 2021, for individual and cluster RCTs comparing de-implementation interventions to usual care, another intervention, or placebo. We applied independent duplicate assessment of eligibility, study characteristics, outcomes, intervention categories, implementation theories, and risk of bias. RESULTS: Of the 227 eligible trials, 145 (64%) were cluster randomized trials (median 24 clusters; median follow-up time 305 days), and 82 (36%) were individually randomized trials (median follow-up time 274 days). Of the trials, 118 (52%) were published after 2010, 149 (66%) were conducted in a primary care setting, 163 (72%) aimed to reduce the use of drug treatment, 194 (85%) measured the total volume of care, and 64 (28%) low-value care use as outcomes. Of the trials, 48 (21%) described a theoretical basis for the intervention, and 40 (18%) had the study tailored by context-specific factors. Of the de-implementation interventions, 193 (85%) were targeted at physicians, 115 (51%) tested educational sessions, and 152 (67%) multicomponent interventions. Missing data led to high risk of bias in 137 (60%) trials, followed by baseline imbalances in 99 (44%), and deficiencies in allocation concealment in 56 (25%). CONCLUSIONS: De-implementation trials were mainly conducted in primary care and typically aimed to reduce low-value drug treatments. Limitations of current de-implementation research may have led to unreliable effect estimates and decreased clinical applicability of studied de-implementation strategies. We identified potential research gaps, including de-implementation in secondary and tertiary care settings, and interventions targeted at other than physicians. Future trials could be improved by favoring simpler intervention designs, better control of potential confounders, larger number of clusters in cluster trials, considering context-specific factors when planning the intervention (tailoring), and using a theoretical basis in intervention design. REGISTRATION: OSF Open Science Framework hk4b2 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13012-022-01238-z. BioMed Central 2022-10-01 /pmc/articles/PMC9526943/ /pubmed/36183140 http://dx.doi.org/10.1186/s13012-022-01238-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Systematic Review
Raudasoja, Aleksi J.
Falkenbach, Petra
Vernooij, Robin W. M.
Mustonen, Jussi M. J.
Agarwal, Arnav
Aoki, Yoshitaka
Blanker, Marco H.
Cartwright, Rufus
Garcia-Perdomo, Herney A.
Kilpeläinen, Tuomas P.
Lainiala, Olli
Lamberg, Tiina
Nevalainen, Olli P. O.
Raittio, Eero
Richard, Patrick O.
Violette, Philippe D.
Komulainen, Jorma
Sipilä, Raija
Tikkinen, Kari A. O.
Randomized controlled trials in de-implementation research: a systematic scoping review
title Randomized controlled trials in de-implementation research: a systematic scoping review
title_full Randomized controlled trials in de-implementation research: a systematic scoping review
title_fullStr Randomized controlled trials in de-implementation research: a systematic scoping review
title_full_unstemmed Randomized controlled trials in de-implementation research: a systematic scoping review
title_short Randomized controlled trials in de-implementation research: a systematic scoping review
title_sort randomized controlled trials in de-implementation research: a systematic scoping review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526943/
https://www.ncbi.nlm.nih.gov/pubmed/36183140
http://dx.doi.org/10.1186/s13012-022-01238-z
work_keys_str_mv AT raudasojaaleksij randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT falkenbachpetra randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT vernooijrobinwm randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT mustonenjussimj randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT agarwalarnav randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT aokiyoshitaka randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT blankermarcoh randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT cartwrightrufus randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT garciaperdomoherneya randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT kilpelainentuomasp randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT lainialaolli randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT lambergtiina randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT nevalainenollipo randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT raittioeero randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT richardpatricko randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT violettephilipped randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT komulainenjorma randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT sipilaraija randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview
AT tikkinenkariao randomizedcontrolledtrialsindeimplementationresearchasystematicscopingreview